United States Patent 10,213,513: Claim Construction, Validity Signals, and Competitive Patent Landscape
What does US 10,213,513 claim, in concrete terms?
US 10,213,513 claims a specific therapeutic method for myeloma using albumin-bound paclitaxel nanoparticles that are complexed with an anti-CD38 polypeptide antibody, with explicit control of particle size and antibody dosing range.
Core method claim (Claim 1) elements
Claim 1 requires all of the following:
- Target condition: “treating a mammal having myeloma”
- Therapeutic construct: administering a composition comprising
- nanoparticles containing albumin-bound paclitaxel
- complexed with an anti-CD38 polypeptide antibody
- Particle size constraint: “average diameter of less than 1 μm”
- Dose-to-effect definition: “effective amount … that treats the myeloma”
- Explicit antibody dose range: “effective amount for the anti-CD38 polypeptide antibody is about 5 mg/kg to about 20 mg/kg”
This is not a generic antibody-paclitaxel combination claim. It is a hybrid targeting + formulation + dosing claim tied to a particular nanoparticle architecture and CD38-specific antibody payload.
Dependent claim hardening (Claims 2 to 11)
Dependent claims add narrow requirements:
- Claim 2: antibody identity is limited to daratumumab or MOR202 or SAR650984
- Claim 3: administration by injection
- Claim 4: particle size is narrowed further to 0.1 μm to 0.3 μm
- Claim 5: albumin and paclitaxel amount is limited to 50 mg/m² to 150 mg/m² (albumin and paclitaxel, as recited)
- Claim 6: mammal is human
- Claim 7: composition includes a pharmaceutically acceptable excipient
- Claim 8: excipient includes saline, water, lactic acid, mannitol, or combination
- Claim 9: therapeutic outcome includes increased progression-free survival
- Claim 10: antibody amount is about 2 mg/mL
- Claim 11: nanoparticle-to-antibody concentration ratio is 5:2
Practical reading for freedom-to-operate (FTO): the more dependent claims you rely on in product design, the more you must match tight quantitative parameters (size window, mg/kg band, mg/mL level, excipient set, ratio).
What is the claim’s likely “center of gravity” for scope and enforcement?
The enforcement leverage is concentrated in three claim anchors:
- CD38-binding antibody complexed to albumin-bound paclitaxel nanoparticles
- Nanoparticle size limits (<1 μm; optionally 0.1–0.3 μm)
- Antibody dose range (5–20 mg/kg), with additional composition-specific constraints in dependent claims
A competitor can sometimes avoid a claim by changing one anchor, but the claim is built as a method-of-treatment claim, which can be difficult to design around if the therapeutic regimen must target CD38 with a paclitaxel-albumin nanoparticle platform.
How strong are the claim validity signals based on the structure of the limitations?
Without the full prosecution history, specification details, and the citation set from the issued patent, it is not possible to do an evidentiary validity opinion. What can be done is a critical landscape read based on typical US patentability bottlenecks for claims of this type.
High-risk patentability features (likely scrutiny points)
-
Combination claims with known components
- Paclitaxel in albumin-bound nanoparticle form is a known formulation paradigm in oncology.
- Anti-CD38 antibodies such as daratumumab are known agents in myeloma.
- The combination can be argued as an “obvious to try” or predictable pairing unless the specification provides non-obvious synergy tied to the claimed formulation architecture and dose regime.
-
Formulation parameter limits
- The claim uses particle diameter thresholds and a narrow window (dependent claim).
- Such limits can help non-obviousness, but they also invite validity challenges if earlier art discloses overlapping size distributions or measurement methods.
-
Dose range and dose definition
- Claim 1 defines the antibody effective amount as 5–20 mg/kg.
- Dose ranges often face “ranges” prior-art issues: if earlier clinical dosing lies inside or overlaps the recited band, the claim can be vulnerable unless the specification shows a specific, unexpected therapeutic advantage tied to that range.
-
Antibody identity restrictions
- Claim 2 limits antibody to daratumumab/MOR202/SAR650984. Identity narrowing can reduce prior art overlap but can also reflect that the prior art already disclosed those antibodies in other nanoparticle contexts.
-
Composition ratio and concentration (Claims 10–11)
- “2 mg/mL” and “5:2” ratio are concrete. If prior art discloses compositions meeting those parameters or teaches those formulation ratios as routine, those limits may not save validity.
“Non-obviousness” needs to show formulation-specific benefit
For a claim like this to survive combination and ranges scrutiny, the patent must support a clear basis that the complexed nanoparticle + CD38 binding yields a tangible therapeutic improvement tied to the claimed particle size and dosing (Claim 9: progression-free survival). Without that evidentiary nexus, the claim risks being treated as an aggregation of known elements.
How does the claim map to competitive design choices?
This patent creates a fence around both the biologic targeting strategy and the delivery format.
Design changes that likely impact infringement risk
- Change the antibody targeting axis away from CD38 (even if CD38 is a common myeloma target)
- Avoid “complexed with” formulation geometry:
- If the antibody is merely co-administered without complexing to the nanoparticles, infringement is harder to support (method claim requires the composition comprises nanoparticles “complexed with” an antibody)
- Move nanoparticle size outside claimed limits:
- Claim 1: less than 1 μm
- Claim 4: 0.1–0.3 μm
- Move antibody dosing outside 5–20 mg/kg
- Move away from albumin-bound paclitaxel nanoparticles to a different carrier or different drug presentation
Design changes that likely still trigger risk
- Using daratumumab and albumin-bound paclitaxel nanoparticle system while altering only excipients or administration route can still land within scope if particle size and dosing remain in-range.
What is the competitive patent landscape likely to look like?
US 10,213,513’s claim structure suggests it sits at the intersection of three patent “families” that typically generate dense coverage:
- CD38-targeting antibodies in myeloma
- Core antibody patents have broad method coverage (administration of daratumumab and analogs), but usually not nanoparticle-complexing limitations.
- Albumin-bound paclitaxel nanoparticle formulation and manufacturing
- Formulation patents often cover particle size distribution, albumin-paclitaxel binding, and reproducible preparation. They may or may not address antibody complexing.
- Antibody-drug nanoparticle targeting
- There is a common patent theme: attaching antibodies to drug-loaded carriers to improve biodistribution and tumor uptake. Overlap risk is high because “antibody-nanoparticle” is a generic scaffold.
Because US 10,213,513 requires all three (albumin-bound paclitaxel nanoparticle + anti-CD38 antibody complex + size and dose parameters), direct hit prior art has to disclose the same or substantially similar hybrid construct.
Practical claim-to-landscape pressure points for competitors
Pressure point A: CD38 antibody identity vs. generic CD38 binding
Claim 2 ties the antibody to daratumumab/MOR202/SAR650984. If a competitor uses a different CD38 antibody, the direct dependent claim may not be implicated, but Claim 1 still covers “anti-CD38 polypeptide antibody.” So the independent claim keeps enforcement leverage against other CD38 antibodies if the formulation matches.
Pressure point B: sizing and characterization
Particle size is a measurable property and often is a litigation focal point. Competitors commonly vary formulation to hit a target size window. Here, the patent explicitly uses a submicron cutoff and a narrow 0.1–0.3 μm band.
Pressure point C: dosing regime
Dose band is a classic hook for both efficacy and design-around. If a competitor’s clinical regimen uses an antibody dose outside 5–20 mg/kg, it may attempt to avoid Claim 1’s dosing limitation. Claim 10 adds concentration specificity (2 mg/mL), which may be harder to evade if it reflects a typical reconstitution or dosing concentration.
Pressure point D: “complexed with” as a structural limitation
This is the most pathway-dependent limitation. If the antibody is not physically associated with the nanoparticle surface or not formed as a stable complex, an infringement argument can narrow quickly. Competitors often route around by:
- covalent vs. noncovalent attachment changes
- different adsorption chemistries
- decoupling the antibody from the particle prior to administration
- using a different coupling approach not meeting “complexed with” interpretation
Key commercial takeaways for R&D and investment decisions
- The claim is not broad at the formulation level. It is anchored to a very specific nanoparticle architecture: albumin-bound paclitaxel complexed with anti-CD38 antibody, with submicron size constraints.
- The enforcement posture is dose- and size-sensitive. A competitor strategy that keeps dosing and size outside the claimed ranges is materially relevant to infringement risk, assuming “complexed with” is also avoided.
- Dependent claims provide additional narrowing but still map to a common product profile. If a product matches multiple dependent limits (0.1–0.3 μm, daratumumab identity, injection, excipient set, 2 mg/mL, 5:2 ratio), the risk concentrates sharply.
Key Takeaways
- US 10,213,513 claims a method for myeloma that requires albumin-bound paclitaxel nanoparticles complexed with an anti-CD38 antibody, with submicron particle diameter and an anti-CD38 dosing band of 5–20 mg/kg.
- The patent narrows further via dependent claims to daratumumab/MOR202/SAR650984, a 0.1–0.3 μm size window, and specific formulation quantities (50–150 mg/m² albumin and paclitaxel; antibody at ~2 mg/mL; nanoparticle-to-antibody 5:2 ratio).
- The most exploitable design-around levers are (i) particle size, (ii) antibody dosing regimen, and (iii) whether the antibody is truly “complexed” to the nanoparticles as required.
- Combination-obviousness risk exists structurally because the claim merges known myeloma CD38 biology with a known albumin-bound paclitaxel delivery paradigm, so the specification must support a strong, formulation-linked benefit to defend against obviousness/range challenges.
FAQs
-
Is this patent limited to daratumumab?
No. Daratumumab is one option via dependent Claim 2, but the independent Claim 1 covers any anti-CD38 polypeptide antibody if the rest of the formulation and dosing limits match.
-
What is the main quantitative infringement trigger besides the antibody dose?
Nanoparticle average diameter: less than 1 μm in Claim 1, and 0.1–0.3 μm in dependent Claim 4.
-
Can co-administration avoid infringement?
Likely yes if the antibody is not “complexed with” the nanoparticles as required by the claim. Co-administration without complexing is a common route around for “composition comprising complexed” limitations.
-
Do the excipient limitations matter for scope?
They matter for dependent Claim 8 only. If a product does not use the recited excipients, it may avoid Claim 8 but still face exposure under broader independent Claim 1.
-
Which dependent claims are most operationally constraining for developers?
Those with hard numbers: Claim 4 (size window), Claim 5 (mg/m² for albumin/paclitaxel), Claim 10 (2 mg/mL antibody), and Claim 11 (5:2 ratio).
References
[1] US Patent 10,213,513 (claims provided in prompt).
